Show simple item record

dc.contributor.authorGupta, A
dc.contributor.authorDunlop, A
dc.contributor.authorMitchell, A
dc.contributor.authorMcQuaid, D
dc.contributor.authorNill, S
dc.contributor.authorBarnes, H
dc.contributor.authorNewbold, K
dc.contributor.authorNutting, C
dc.contributor.authorBhide, S
dc.contributor.authorOelfke, U
dc.contributor.authorHarrington, KJ
dc.contributor.authorWong, KH
dc.date.accessioned2022-01-25T13:34:20Z
dc.date.available2022-01-25T13:34:20Z
dc.date.issued2021-11-19
dc.identifier.citationClinical and translational radiation oncology, 2022, 32 pp. 48 - 51
dc.identifier.issn2405-6308
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4973
dc.identifier.eissn2405-6308
dc.identifier.eissn2405-6308
dc.identifier.doi10.1016/j.ctro.2021.11.001
dc.identifier.doi10.1016/j.ctro.2021.11.001
dc.description.abstractINTRODUCTION: The Elekta Unity MR-Linac (MRL) has enabled adaptive radiotherapy (ART) for patients with head and neck cancers (HNC). Adapt-To-Shape-Lite (ATS-Lite) is a novel Adapt-to-Shape strategy that provides ART without requiring daily clinician presence to perform online target and organ at risk (OAR) delineation. In this study we compared the performance of our clinically-delivered ATS-Lite strategy against three Adapt-To-Position (ATP) variants: Adapt Segments (ATP-AS), Optimise Weights (ATP-OW), and Optimise Shapes (ATP-OS). METHODS: Two patients with HNC received radical-dose radiotherapy on the MRL. For each fraction, an ATS-Lite plan was generated online and delivered and additional plans were generated offline for each ATP variant. To assess the clinical acceptability of a plan for every fraction, twenty clinical goals for targets and OARs were assessed for all four plans. RESULTS: 53 fractions were analysed. ATS-Lite passed 99.9% of mandatory dose constraints. ATP-AS and ATP-OW each failed 7.6% of mandatory dose constraints. The Planning Target Volumes for 54 Gy (D95% and D98%) were the most frequently failing dose constraint targets for ATP. ATS-Lite median fraction times for Patient 1 and 2 were 40 mins 9 s (range 28 mins 16 s - 47 mins 20 s) and 32 mins 14 s (range 25 mins 33 s - 44 mins 27 s), respectively. CONCLUSIONS: Our early data show that the novel ATS-Lite strategy produced plans that fulfilled 99.9% of clinical dose constraints in a time frame that is tolerable for patients and comparable to ATP workflows. Therefore, ATS-Lite, which bridges the gap between ATP and full ATS, will be further utilised and developed within our institute and it is a workflow that should be considered for treating patients with HNC on the MRL.
dc.formatElectronic-eCollection
dc.format.extent48 - 51
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER IRELAND LTD
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleOnline adaptive radiotherapy for head and neck cancers on the MR linear Accelerator: Introducing a novel modified Adapt-to-Shape approach.
dc.typeJournal Article
dcterms.dateAccepted2021-11-04
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1016/j.ctro.2021.11.001
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.relation.isPartOfClinical and translational radiation oncology
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/ImmNet
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radiotherapy Physics Modelling
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublished
pubs.volume32
pubs.embargo.termsNot known
icr.researchteamRadiotherapy Physics Modelling
icr.researchteamTargeted Therapy
dc.contributor.icrauthorNill, Simeon
dc.contributor.icrauthorBhide, Shreerang
dc.contributor.icrauthorHarrington, Kevin


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0